Friday, 4 November 2016

Novo Nordisk defends U.S. diabetes drug pricing

COPENHAGEN (Reuters) - Danish diabetes drug maker Novo Nordisk on Friday defended its pricing of diabetes drugs after facing allegations of pricing collusion by U.S. senators.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)